Drug Profile

TAK 101

Alternative Names: CNP-101; Cour-NP-GLI; TAK-101; TIMP-GLIA; TIMP/Gliadin

Latest Information Update: 05 Nov 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Cour Pharmaceutical Development
Developer Cour Pharmaceutical Development; Takeda
Class Digestion aids; Polymers; Proteins
Mechanism of Action Immunomodulators; T cell activation inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II Coeliac disease

Most Recent Events

23 Jun 2022 Phase-II clinical trials in Coeliac disease (Prevention, In adults, In the elderly) in USA (IV) (NCT04530123)
11 May 2021 Takeda expects approval for Coeliac disease in FY 2025 (Takeda pipeline, May 2021)
09 Mar 2021 Phase-II development is ongoing in in Coeliac disease in USA (IV) (NCT03738475)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com